会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • 9-SUBSTITUIERTE 2,3-BENZODIAZEPINE
    • 9-取代的2,3-苯并二氮杂
    • WO2015121230A1
    • 2015-08-20
    • PCT/EP2015/052709
    • 2015-02-10
    • BAYER PHARMA AKTIENGESELLSCHAFT
    • SIEGEL, StephanBÄURLE, StefanCLEVE, ArwedHAENDLER, BernardFERNÁNDEZ-MONTALVÁN, Amaury Ernesto
    • C07D243/02A61K31/551A61P35/00
    • C07D243/02
    • Es werden Bromodomänen-proteininhibitorische, insbesondere BET-proteininhibitorische sowie bevorzugt BRD4-inhibitorische 9-substituierte 2,3-Benzodiazepine, der allgemeinen Formel (I), in der R 1a , R 1b , R 1c , R 2 , R 3 , R 4 , R 5 und R 6 die in der Beschreibung angegebenen Bedeutungen haben, pharmazeutische Mittel enthaltend die erfindungsgemäßen Verbindungen sowie deren prophylaktische und therapeutische Verwendung bei hyper-proliferativen Erkrankungen, insbesondere bei Tumorerkrankungen beschrieben. Desweiteren wird die Verwendung von BET-Proteininhibitoren in benignen Hyperplasien, atherosklerotische Erkrankungen, Sepsis, Autoimmunerkrankungen, Gefäßerkrankungen, viralen Infektionen, in neurodegenerativen Erkrankungen, in inflammatorischen Erkrankungen, in atherosklerotischen Erkrankungen und in der männlichen Fertilitätskontrolle beschrieben.
    • 有溴基结构域-proteininhibitorische,特别是BET-proteininhibitorische和优选BRD4抑制9-取代的通式(I)的2,3-苯二氮类,其中R1A,R1B,R1C,R2,R3,R4,R5和R6在 说明书中给出的含义,包含化合物以及在本发明中过度增殖性疾病的预防和治疗用途,特别是描述肿瘤疾病的药物组合物。 此外,使用在良性增生BET蛋白抑制剂,动脉粥样硬化性疾病,败血症,自身免疫性疾病,血管疾病,病毒感染,神经退行性疾病,在动脉粥样硬化疾病和男性节育描述炎性疾病。
    • 5. 发明申请
    • SPIROINDOLINE DERIVATIVES FOR USE AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS
    • 用于促性腺激素释放激素受体拮抗剂的螺旋体衍生物
    • WO2014166958A1
    • 2014-10-16
    • PCT/EP2014/057079
    • 2014-04-08
    • BAYER PHARMA AKTIENGESELLSCHAFT
    • PANKNIN, OlafRING, SvenBÄURLE, StefanWAGENFELD, AndreaNUBBEMEYER, ReinhardNOWAK-REPPEL, KatrinLANGER, Gernot
    • C07D495/10A61K31/407A61P5/04
    • C07D495/10
    • Spiroindoline derivatives, processes for their preparation and pharmaceutical compositions thereof, their use for the treatment of diseases, and their use for the manufacture of medicaments for the treatment of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine leiomyoma (fibroids), polycystic ovarian disease, menorrhagia, dysmenorrhea, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception, infertility and assisted reproductive therapy such as in vitro fertilization. The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.
    • 螺二氢吲哚衍生物,其制备方法及其药物组合物,其用于治疗疾病的用途及其用于制备用于治疗男性和女性中的疾病,特别是性激素相关疾病的药物,特别是那些 选自子宫内膜异位症,子宫平滑肌瘤(子宫肌瘤),多囊性卵巢疾病,月经过多,痛经,多毛症,早熟性青春期,性腺类固醇依赖性肿瘤,如前列腺癌,乳腺和卵巢癌,性腺垂体腺瘤,睡眠呼吸暂停,易怒 肠综合征,经前期综合征,良性前列腺肥大,避孕,不育症和辅助生殖治疗如体外受精。 本申请特别涉及作为促性腺激素释放激素(GnRH)受体拮抗剂的螺二氢吲哚衍生物。
    • 7. 发明申请
    • SPIRO[INDOLIN-3,4'-PIPERIDINE] DERIVATIVES AS GNRH RECEPTOR ANTAGONISTS
    • 作为GNRH受体拮抗剂的SPIRO [吲哚-3,4'-哌啶]衍生物
    • WO2015091315A1
    • 2015-06-25
    • PCT/EP2014/077680
    • 2014-12-15
    • BAYER PHARMA AKTIENGESELLSCHAFT
    • PANKNIN, OlafBÄURLE, StefanRING, SvenSCHWEDE, WolfgangSCHMEES, NorbertNOWAK-REPPEL, KatrinLANGER, Gernot
    • C07D471/10A61K31/438A61P15/00A61P5/24
    • C07D471/10
    • Spiroindoline-piperidine derivatives of formula (I) as gonadotropin- releasing hormone (GnRH) receptor antagonists, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selcted from the group of endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reproductive therapy such as in vitro fertilization). The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.
    • 式(I)的螺二氢吲哚 - 哌啶衍生物作为促性腺激素释放激素(GnRH)受体拮抗剂,其制备方法及其药物组合物,其用于治疗和/或预防疾病的用途及其用于制备药物的用途 治疗和/或预防男性和女性中特别是性激素相关疾病的治疗和/或预防,特别是从子宫内膜异位症,子宫肌瘤,多囊卵巢疾病,多毛症,早熟性青春期,性腺类固醇依赖性肿瘤等中筛选出的疾病,特别是性激素相关疾病 作为前列腺,乳腺和卵巢的癌症,促性腺垂体腺瘤,睡眠呼吸暂停,肠易激综合征,经前期综合征,良性前列腺肥大,避孕和不孕症(例如,辅助生殖治疗如体外受精)。 本申请特别涉及作为促性腺激素释放激素(GnRH)受体拮抗剂的螺二氢吲哚衍生物。